Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 134.25 percent decrease over earnings of $1.81 per share from the same period last year.
Needham Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $16 to $6.